Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Tempus AI, Inc. (NASDAQ:TEM) has received an average recommendation of “Moderate Buy” from the twelve analysts that are currently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $56.36.

A number of equities analysts have recently weighed in on the company. Loop Capital cut their target price on Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a research note on Tuesday, January 14th. Stifel Nicolaus downgraded Tempus AI from a “buy” rating to a “hold” rating and boosted their target price for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Wolfe Research assumed coverage on Tempus AI in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Bank of America upped their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a research note on Tuesday, January 14th.

Insider Buying and Selling

In other news, major shareholder Bradley A. Keywell sold 265,000 shares of Tempus AI stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the transaction, the insider now directly owns 15,218,365 shares of the company’s stock, valued at $534,164,611.50. The trade was a 1.71 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Eric P. Lefkofsky sold 476,209 shares of the firm’s stock in a transaction that occurred on Wednesday, January 22nd. The stock was sold at an average price of $49.84, for a total transaction of $23,734,256.56. Following the sale, the chief executive officer now owns 6,502,643 shares in the company, valued at approximately $324,091,727.12. The trade was a 6.82 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862,758 shares of company stock worth $79,585,675.

Hedge Funds Weigh In On Tempus AI

Hedge funds have recently modified their holdings of the company. Apollon Wealth Management LLC bought a new position in shares of Tempus AI during the fourth quarter worth $256,000. Sumitomo Mitsui Trust Group Inc. lifted its position in Tempus AI by 166.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock valued at $109,352,000 after purchasing an additional 2,021,394 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Tempus AI during the fourth quarter valued at $178,000. James J. Burns & Company LLC bought a new position in Tempus AI during the fourth quarter valued at $236,000. Finally, abrdn plc purchased a new stake in shares of Tempus AI in the fourth quarter valued at $2,784,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Trading Down 0.5 %

TEM stock opened at $50.77 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI has a 52-week low of $22.89 and a 52-week high of $79.49. The business has a 50-day simple moving average of $44.11 and a two-hundred day simple moving average of $47.97.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.